HK1 and cancer: We conclude (i) that inhibition of HK2-driven glycolysis, OXPHOS, and FAO is likely to be a pan-tumor precision therapy approach to HK1−HK2+ tumors, regardless of their tissue of origin, and (ii) that cancer therapies that involve HK2 inhibition will be restricted to tumors that do not express HK1.